|Day Low/High||49.40 / 49.59|
|52 Wk Low/High||34.41 / 50.63|
First-ever 510(k)-cleared fentanyl enzyme immunoassay brings high-performance qualitative screening to a wide range of healthcare settings
Earnings help boost markets as D.C. isn't counted on for much of anything. Portfolio action (it was a busy week) includes a new position and a downgrade.
Abbott CEO Miles White said on an earnings call the company will make one more asset sale as part of efforts to gain regulatory approval for the Abbott-Alere deal.
Abbott will report second-quarter numbers on Thursday as it completes the Alere deal. $ABT $ALR
Rapid Urine Test Facilitates Real-time Monitoring of Use, Misuse and Abuse of Clinically Relevant Prescription Pain and Addiction Therapies
The Triage assets are being divested in order to secure antitrust approvals for Abbott Laboratories' purchase of Alere.
What we'll be looking for from ABT, NUE, DHR, KEY, SNA, GE and SLB.
The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 496,718 share increase in total short interest for Alere Inc. , to 3,374,652, an increase of 17.26% since 06/15/2017.
Jobs report and Fed minutes highlight a short week. In the portfolio, we add one name and downgrade another.
The final vote results will be filed on a Form 8-K with the Securities and Exchange Commission.
Tech rotation, oil and Fed rate hike keep markets on even (make that flat) keel. Several portfolio positions get beefed up.
In turn, this will increase the company's profit margins.
After a busy Thursday, markets look forward to economic data and the Fed meeting next week. In the portfolio, we dropped a tech stock and added a healthcare name.
Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
David Einhorn is going all-in on General Motors.
New test provides powerful tool to help meet malaria eradication goals
Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.
Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.